Nutex Health (NASDAQ:NUTX) Issues Earnings Results, Beats Expectations By $2.48 EPS

Nutex Health (NASDAQ:NUTX) announced its quarterly earnings results on Tuesday. The company reported ($2.95) EPS for the quarter, beating the consensus estimate of ($5.43) by $2.48, Zacks reports. Nutex Health had a return on equity of 42.08% and a net margin of 10.76%.

Nutex Health Trading Down 4.6%

Shares of NASDAQ:NUTX traded down $4.75 during trading on Tuesday, hitting $99.20. 162,425 shares of the company’s stock were exchanged, compared to its average volume of 145,360. The company has a current ratio of 2.27, a quick ratio of 2.26 and a debt-to-equity ratio of 1.02. The firm has a market cap of $551.06 million, a P/E ratio of 8.34 and a beta of -0.23. The firm has a 50-day moving average price of $107.60 and a two-hundred day moving average price of $113.43. Nutex Health has a 1-year low of $27.29 and a 1-year high of $184.27.

Institutional Trading of Nutex Health

A number of institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets raised its position in shares of Nutex Health by 966.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 320 shares of the company’s stock valued at $40,000 after acquiring an additional 290 shares during the last quarter. Bank of America Corp DE boosted its position in shares of Nutex Health by 6,590.3% in the 4th quarter. Bank of America Corp DE now owns 2,074 shares of the company’s stock worth $66,000 after purchasing an additional 2,043 shares during the last quarter. Vestcor Inc acquired a new stake in shares of Nutex Health during the third quarter worth $111,000. New York State Common Retirement Fund bought a new stake in Nutex Health in the second quarter valued at about $137,000. Finally, Raymond James Financial Inc. acquired a new position in Nutex Health in the second quarter valued at about $142,000. Institutional investors and hedge funds own 5.32% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on NUTX shares. Weiss Ratings reissued a “hold (c-)” rating on shares of Nutex Health in a report on Wednesday, October 8th. Wall Street Zen lowered shares of Nutex Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 18th. Finally, Maxim Group set a $205.00 target price on Nutex Health and gave the stock a “buy” rating in a report on Tuesday, August 26th. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $252.50.

About Nutex Health

Nutex Health Inc operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management.